AN2 Therapeutics Inc (ANTX) - Net Assets
Based on the latest financial reports, AN2 Therapeutics Inc (ANTX) has net assets worth $53.06 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($61.95 Million) and total liabilities ($8.89 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ANTX asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $53.06 Million |
| % of Total Assets | 85.65% |
| Annual Growth Rate | 49.17% |
| 5-Year Change | -14.29% |
| 10-Year Change | N/A |
| Growth Volatility | 804.28 |
AN2 Therapeutics Inc - Net Assets Trend (2019–2025)
This chart illustrates how AN2 Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore AN2 Therapeutics Inc balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for AN2 Therapeutics Inc (2019–2025)
The table below shows the annual net assets of AN2 Therapeutics Inc from 2019 to 2025. For live valuation and market cap data, see AN2 Therapeutics Inc (ANTX) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $53.06 Million | -35.17% |
| 2024-12-31 | $81.85 Million | -34.36% |
| 2023-12-31 | $124.70 Million | +30.75% |
| 2022-12-31 | $95.37 Million | +54.05% |
| 2021-12-31 | $61.91 Million | +2150.38% |
| 2020-12-31 | $2.75 Million | -42.84% |
| 2019-12-31 | $4.81 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to AN2 Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 23514900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $57.00K | 0.11% |
| Other Components | $293.95 Million | 554.00% |
| Total Equity | $53.06 Million | 100.00% |
AN2 Therapeutics Inc Competitors by Market Cap
The table below lists competitors of AN2 Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zeder Investments Ltd
JSE:ZED
|
$109.65 Million |
|
X Financial Class A
NYSE:XYF
|
$109.69 Million |
|
GAM Holding AG
SW:GAM
|
$109.70 Million |
|
Sat Industries Limited
NSE:SATINDLTD
|
$109.77 Million |
|
Trans Power Marine Tbk
JK:TPMA
|
$109.61 Million |
|
KOLIBRI GLOBAL ENERGY INC
F:B120
|
$109.61 Million |
|
I-Berhad
KLSE:4251
|
$109.58 Million |
|
Gold Rain Enterprises
TWO:4503
|
$109.55 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AN2 Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 81,849,000 to 53,060,000, a change of -28,789,000 (-35.2%).
- Net loss of 35,174,000 reduced equity.
- Other comprehensive income increased equity by 26,000.
- Other factors increased equity by 6,359,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-35.17 Million | -66.29% |
| Other Comprehensive Income | $26.00K | +0.05% |
| Other Changes | $6.36 Million | +11.98% |
| Total Change | $- | -35.17% |
Book Value vs Market Value Analysis
This analysis compares AN2 Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.67x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 18.22x to 2.67x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.26 | $4.68 | x |
| 2020-12-31 | $0.15 | $4.68 | x |
| 2021-12-31 | $3.30 | $4.68 | x |
| 2022-12-31 | $6.22 | $4.68 | x |
| 2023-12-31 | $5.28 | $4.68 | x |
| 2024-12-31 | $2.74 | $4.68 | x |
| 2025-12-31 | $1.76 | $4.68 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AN2 Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -66.29%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.17x
- Recent ROE (-66.29%) is above the historical average (-207.99%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -702.47% | 0.00% | 0.00x | 1.18x | $-34.29 Million |
| 2020 | -494.37% | 0.00% | 0.00x | 1.54x | $-13.88 Million |
| 2021 | -34.69% | 0.00% | 0.00x | 1.06x | $-27.66 Million |
| 2022 | -43.48% | 0.00% | 0.00x | 1.08x | $-51.01 Million |
| 2023 | -51.91% | 0.00% | 0.00x | 1.11x | $-77.20 Million |
| 2024 | -62.70% | 0.00% | 0.00x | 1.13x | $-59.51 Million |
| 2025 | -66.29% | 0.00% | 0.00x | 1.17x | $-40.48 Million |
Industry Comparison
This section compares AN2 Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AN2 Therapeutics Inc (ANTX) | $53.06 Million | -702.47% | 0.17x | $109.62 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About AN2 Therapeutics Inc
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15… Read more